Acceptability: dropouts during intervention period Rate of dropouts and adverse events · Patients with idiopathic Parkinson's disease
1 finding from 1 review
Activity Gait speed · people with Parkinson's disease
2 findings from 1 review
walking distance in m (at the end of study; all studies) ‐ Active control group (co‐interventions were similar in both groups) Measures of timed gait. Scale from: 0 to inf. · people with Parkinson's disease
2 findings from 1 review
acceptability and safety of treadmill training ‐ Active control group (co‐interventions were similar in both groups) Number of adverse events and drop‐outs · people with Parkinson's disease
1 finding from 1 review
acceptability and safety of treadmill training ‐ No intervention control group (co‐interventions were not similar in both groups) Number of adverse events and drop‐outs · people with Parkinson's disease
1 finding from 1 review
Intervention not reported
Tremor severityClinical rating scale. Scale from 0 to 4 · patients with essential tremor
1 finding from 1 review
Intervention not reported
Withdrawals due to adverse events · patients with essential tremor
1 finding from 1 review
Intervention not reported
Quality of life Investigator global assessment Scale from 1 to 7 · patients with essential tremor
1 finding from 1 review
Intervention not reported
Subjective impact of fatigue on ADL, fatigue severity (post‐intervention) · people with Parkinson's disease
1 finding from 1 review
Intervention not reported
Nausea (adverse effect, post‐intervention) · people with Parkinson's disease
The intervention showed no clear difference in nausea (adverse effect, post‐intervention) (moderate certainty).
1 finding from 1 review
Intervention not reported
HRQOL (post‐intervention) · people with Parkinson's disease
1 finding from 1 review
Intervention not reported
Subjective impact of physical fatigue on ADL (post‐intervention) · people with Parkinson's disease
1 finding from 1 review
Intervention not reported
Anxiety (adverse effect, post‐intervention) · people with Parkinson's disease
The intervention leads to lower anxiety (adverse effect, post‐intervention) (high certainty).
1 finding from 1 review
Intervention not reported
Headache (adverse effect, post‐intervention) · people with Parkinson's disease
The intervention showed no clear difference in headache (adverse effect, post‐intervention) (moderate certainty).
1 finding from 1 review
Intervention not reported
Hypertension (adverse effect, post‐intervention) · people with Parkinson's disease
The intervention showed no clear difference in hypertension (adverse effect, post‐intervention) (moderate certainty).
1 finding from 1 review
Intervention not reported
Impulse control disorders (adverse effect, post‐intervention) · people with Parkinson's disease
The intervention showed no clear difference in impulse control disorders (adverse effect, post‐intervention) (moderate certainty).
1 finding from 1 review
Intervention not reported
Nausea (adverse effect, post‐intervention) · people with Parkinson's disease
The intervention showed no clear difference in nausea (adverse effect, post‐intervention) (moderate certainty).
1 finding from 1 review
Intervention not reported
Orthostatic hypotension (adverse effect, post‐intervention) · people with Parkinson's disease
The intervention showed no clear difference in orthostatic hypotension (adverse effect, post‐intervention) (moderate certainty).
1 finding from 1 review
Intervention not reported
Subjective impact of fatigue on ADL, fatigue severity (post‐intervention) · people with Parkinson's disease
1 finding from 1 review
Intervention not reported
Anxiety (adverse effect, post‐intervention) · people with Parkinson's disease
The intervention showed no clear difference in anxiety (adverse effect, post‐intervention) (moderate certainty).
1 finding from 1 review